Survodutide

ID: survodutide

Aliases: SURVODUTIDE, BI 456906

Type: compound

Route/form: subcutaneous injection in trials

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_rct, mechanistic, meta_analysis, preclinical, review

Linked sources: 7

Broad outcomes: Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GLP-1 receptor agonist
• glucagon receptor agonist

Optimization domains

• metabolic
• obesity
• diabetes
• MASLD

Research basis

• Human phase 2 obesity and diabetes data show weight and glycemic effects for GLP-1/glucagon dual agonism.
• A randomized phase 2 MASH/fibrosis trial gives liver-disease context rather than only scale-weight rationale.
• The glucagon component makes it mechanistically comparable with mazdutide and retatrutide for liver-fat and energy-expenditure hypotheses.

Limits, risks, and missing evidence

• It remains investigational, so label-level safety and long-term outcome data are incomplete.
• Glucagon agonism may affect heart rate, glucose/liver metabolism, and GI tolerability in ways that need trial-context interpretation.
• Liver-histology and obesity endpoints should be kept separate from casual performance or physique claims.

Risk flags

• investigational
• metabolic endocrine
• medical supervision
• injection

Linked papers, labels, and reviews

1. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomized double-blind placebo-controlled dose-finding phase 2 trial
   human_rct / pubmed_survodutide_obesity_phase2_2024
   Human obesity phase 2 trial.
2. Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide in people with type 2 diabetes
   human_rct / pubmed_survodutide_t2d_phase2_2024
   Human diabetes/weight phase 2 dose-response trial.
3. A phase 2 randomized trial of survodutide in MASH and fibrosis
   human_rct / pubmed_survodutide_mash_phase2_2024
   Human liver-disease trial; supports a MASLD/MASH rationale beyond simple scale weight for GLP-1/glucagon dual agonism.
4. Shared mechanistic pathways of glucagon signalling: unlocking its potential for treating obesity and MASLD
   review / pubmed_glucagon_signalling_masld_review_2025
   Mechanism review for glucagon agonism as a component of dual/triple agonist metabolic and liver-fat programs.
5. Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis
   meta_analysis / pubmed_survodutide_meta_2025
   Meta-analysis of RCTs evaluating survodutide glycemic, weight, waist, lipid, blood-pressure, and adverse-event outcomes.
6. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
   preclinical / pubmed_survodutide_discovery_preclinical_2022
   Discovery/preclinical pharmacology paper for survodutide/BI 456906; receptor agonism and rodent anti-obesity pharmacology support the dual GLP-1/glucagon mechanism.
7. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
   mechanistic / pubmed_survodutide_candidate_selection_2024
   Biomarker and pharmacological profiling paper explaining candidate selection among dual GCGR/GLP-1R agonists; useful mechanism/translation context.